Gyre Therapeutics
GYRE
32 hedge funds and large institutions have $7.3M invested in Gyre Therapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 11 reducing their positions, and 4 closing their positions.
92% more call options, than puts
Call options by funds: $25K | Put options by funds: $13K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 35 → 32 (-3)
47% less capital invested
Capital invested by funds: $13.9M → $7.3M (-$6.59M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
82% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$52.8K |
| 2 |
Morgan Stanley
New York
|
+$723 |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$241 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$68.2K |
| 2 |
DCM
DG Capital Management
New York
|
-$63.4K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$46K |
| 4 |
Renaissance Technologies
New York
|
-$21.7K |
| 5 |
SIM
Spark Investment Management
New York
|
-$14K |
GYRE Hedge Fund Activity: Q1 2016 in Review
32 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2016, worth a combined $7.3M — down 47% from $13.9M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GYRE and 1 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 2 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $52.8K. The largest seller was D.E. Shaw & Co, cutting an estimated $68.2K.
- 32 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2016, down from 35 in Q4 2015.
- Funds reported $7.3M of Gyre Therapeutics stock for Q1 2016, down 47% quarter-over-quarter.
- 1 fund opened new Gyre Therapeutics positions in Q1 2016 and 4 closed out, a net change of -3 holders.
- The largest Gyre Therapeutics buyer in Q1 2016 was T. Rowe Price Associates, an estimated $52.8K added.
- The largest Gyre Therapeutics seller in Q1 2016 was D.E. Shaw & Co, an estimated $68.2K sold.
Based on aggregated 13F filings for Q1 2016.